Latest Breaking News On - Theodora harold - Page 1 : comparemela.com

Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first 2 in 1 immune cell engager CB699 at AACR 2024

Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first 2 in 1 immune cell engager CB699 at AACR 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomCity ofUnited statesDavid daleyMary jane elliottSukaina virjiTheodora haroldRegius professor of cancer researchZai labClinical cancer researchInstitute of cancer researchIp groupCrescendo biologics ltdAmerican association for cancer researchCancer researchAnnual meeting

Crescendo Biologics announces first U S patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC

Crescendo Biologics announces first U S patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomTheodora haroldDavid daleyMary jane elliottIp groupUniversity of washingtonCrescendo biologics ltdZai labFred hutchinson cancer centreFred hutchinson cancerCrescendo biologicsJane elliottSuki virjiSofinnova partnersAndera partnersQuan capital

Crescendo widens pivotal solid tumour therapy trial

Crescendo widens pivotal solid tumour therapy trial
pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.

Sonia benhamidaTheodora haroldIp group biontechAndera partnersSofinnova partnersQuan capitalKreos capitalCrescendo biologics

Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours

Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

United kingdomTheodora haroldSonia benhamidaCrescendo biologics ltdIp group biontechIp groupZai labKreos capitalBiologics ltdSofinnova partnersAndera partnersQuan capitalCrescendo biologics

IP : Crescendo Biologics - Secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours

24 Jul 2023 $32 million additional capital raised, supported by all major existing investors and new investor Kreos Capital .

United kingdomTheodora haroldMelanie toyne sewell adam loudonSonia benhamidaCrescendo biologics ltdZai labIp group biontechIp groupKreos capitalBiologics ltdSofinnova partnersAndera partnersQuan capitalAdam loudonCrescendo biologics